Skip to Content

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

Mezigdomide is a potent, novel cereblon E3 ligase modulator leading to apoptosis in myeloma cells. At the same time, mezigdomide has a powerful synergy with dexamethasone. In this MEDtalk, Paul G. Richardson, Dana-Farber Cancer Institute, Boston, USA, presents the results showing that the combination of mezigdomide and dexamethasone has a manageable safety profile and promising efficacy for patients with triple-class refractory R/R multiple myeloma, including patients with prior BCMA-targeted therapies.

Paul Richardson

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top